Introduction

Vitamin D is a secosteroid hormone which is activated by enzymes and acts via receptors. In the liver, vitamin D is hydroxylated to 25-hydroxyvitamin D3 [25(OH)D3], which is the major circulating and stored form of the hormone and also the form that is measured to determine vitamin D status. A further hydroxylation step is required in the kidneys to convert 25(OH)D3 into the biologically active form of 1.25-dihydroxyvitamin D [1.25(OH)2D3] (1,2). 1.25(OH)2D3 interacts with its vitamin D nuclear receptor which is present in the small intestine, kidneys and other tissues (3,4). In addition to its central role in calcium and bone metabolism, 1.25(OH)2D3 has important effects on the growth and differentiation of many cell types and also on immune regulation (5,6). Low 25(OH)D3 levels appear to increase susceptibility to immune-related disorders such as autoimmune diseases, tuberculosis and cancers. Furthermore, vitamin D deficiency has been suggested to have an active role in the pathogenesis of autoimmune diseases (7,8,9).

There are various experimental models studying the immunomodulatory effects of 1.25(OH)2D3 and its analogues in autoimmune disease. It has been reported that in lpr/lpr mice systemic lupus erythematosus (10), experimental allergic encephalomyelitis (11,12,13), collagen-induced arthritis (14), Lyme disease (15), inflammatory bowel disease (16) and autoimmune diabetes in nonobese diabetic mice could be prevented by administration of 1.25(OH)2D3 and its analogues (17). In experimental models of autoimmune thyroiditis, the additive protective effect of cyclosporin A and 1.25(OH)2D3
administration has been shown (18,19). In the clinical context, it has been postulated that vitamin D deficiency might increase the risk of autoimmune diseases, including Hashimoto’s thyroiditis (HT) (1,2,5,20).

In this study, we aimed to determine if HT patients were vitamin D-deficient by comparing their serum vitamin D levels with those of healthy controls.

Methods

Patients and Controls

The serum vitamin D levels of 90 (67 females and 23 males) newly diagnosed HT patients between ages 3.64 and 17.16 years (mean: 12.32±2.87) who had presented to the Cerrahpaşa Faculty of Medicine Pediatric Endocrinology Clinic were compared with those of an age- and sex-matched healthy control group (n=79) (Table 1). The control group consisted of children who had applied to the general pediatric outpatient clinic of the same hospital with complaints of mild upper respiratory tract infection. The blood samples were drawn between February 2013 and June 2014. In Istanbul, the weather during the months from April to October is quite clear, thus these months were assumed to represent months with enough sun exposure. In the study period of 17 months, 10 months were with enough sun exposure and the subjects in both groups were chosen to be in similar numbers in the same time interval, thus similar with regard to sun exposure. A chi-square test was performed which confirmed that the individuals with HT and those in the control group were distributed homogenously.

None of the patients had been treated with L-thyroxine (LT4) at the time the samples were taken. The diagnosis of HT was based on the following findings: anti thyroid peroxidase (anti-TPO) levels >35 IU/mL, anti-thyroglobulin (anti-Tg) levels >40 IU/mL and parenchymal heterogeneity on thyroid ultrasound. Patients with renal and liver disorders, diabetes mellitus, metabolic bone and parathyroid disorders or epilepsy treated by anticonvulsant therapy and patients on other medications that may alter 25(OH)D3 or 1.25(OH)2D3 metabolism and thyroid functions were excluded. The study was conducted between February 2013 and June 2014 and approved by the Cerrahpaşa Faculty of Medicine Ethics Committee (approval date and number: 2-12-2013/3518). Written informed consent was taken from all parents and from children older than 16 years.

Overt hypothyroidism (OHP) was diagnosed if serum thyroid stimulating hormone (TSH) was >5.7 µU/mL (reference interval: 0.7-5.7 µU/mL) and free T4 (fT4) was <0.7 ng/dL (reference interval: 0.7-4.2 ng/dL). Subclinical hypothyroidism was diagnosed if the serum TSH level was increased (>5.7 µU/mL), but serum fT4 and free triiodothyronine (fT3) (reference interval: 1.8-4.2 pg/mL) levels were within the reference ranges. Overt hyperthyroidism was diagnosed if serum TSH was <0.7 µU/mL and fT4 >1.9 ng/dL. Subclinical hyperthyroidism was diagnosed if serum TSH level was <0.7 µU/mL and serum fT4 and fT3 levels were within normal limits. The patients were considered to be euthyroid if their serum fT4 and TSH levels were within normal limits.

Serum 25(OH)D3 levels ≤20 ng/mL, those between 21-29 ng/mL and ≥30 ng/mL were accepted as vitamin D deficiency, insufficiency and sufficiency, respectively (21). Thus, patients and controls were grouped as 25(OH)D3 deficient, insufficient and sufficient. Patients with 25(OH)D3 deficiency, insufficiency and sufficiency were compared according to their serum TSH, fT3, fT4, total T3, total T4, anti-TPO and anti-Tg levels.

Laboratory Measurements

Serum TSH, total T3, total T4, fT3, fT4, anti-TPO, anti-Tg and 25(OH)D3 levels were measured in venous blood samples. TSH, total and fT4, total and fT3, anti-TPO and anti-Tg were measured by chemiluminescence method using the autoanalyzer Architect (Abbott Laboratories, IL USA).

For measuring 25(OH)D3, venous blood samples were collected into plain tubes, serum was separated and stored at -70 °C for a week until analysis. 25(OH)D3 vitamin levels were measured by the HPLC method using a Shimadzu analyzer (Shimadzu Corporation Kyoto, Tokyo, Japan). The intra- and inter-assay coefficients of variation for 25(OH)D3 were 5.6 and 8.0, respectively. The lower detection for 25(OH)D3 was 4 ng/mL (10 nmol/L). No external standards were used.

Statistics

All statistical analysis were performed by using the software SPSS for Windows V16.0. Vitamin D level distribution was compared with chi-square test between patients and the control group. Seasonal homogeneity of the drawn blood samples of the individuals with HT and the controls were confirmed by chi-square test. Odd ratios between HT and serum 25(OH)D3 levels were calculated by using one variable logistic regression. Comparing means between groups of more than 2 were done by using the Kruskal-Wallis method. Comparison between 2 groups was performed by Mann-Whitney U-test. By using Bonferroni correction, a p-value of 0.016 was accepted as significant between 2 groups. Nonparametric correlations were performed by using Spearman’s test. The data are expressed as means ± standard deviation. A p-value below 0.05 was considered as statistically significant.

Results

Demographic characteristics of the patients with HT and the control group are presented in Table 1. Median 25(OH)D3 level was 16.67 ng/mL (range: 1.5-67.30 ng/mL) for patients with HT and 20.99 ng/mL (range: 5.7-59.20 ng/mL) for the controls (Figure 1). Mean serum 25(OH)D3 level was 16.67±11.65 ng/mL and 20.99±9.86 ng/mL in patients with HT and in the controls, respectively. Mean 25(OH)D3 level was significantly
lower in HT patients as compared with the healthy control group \(p=0.001\). To further evaluate the relationship between 25(OH)D3 levels and HT, the odd ratio between 25(OH)D3 levels and HT was calculated by one variable logistic regression. HT was observed to be more frequent in the individuals with a 25(OH)D3 level <20 ng/mL (OR: 2.28, CI: 1.21-4.3). In patients with HT, the prevalence rates of 25(OH)D3 deficiency, insufficiency and sufficiency were 71\% (\(n=64\)), 17.7\% (\(n=16\)) and 11.1\% (\(n=10\)), respectively. In the control group, these prevalence figures were 51.9\% (\(n=41\)), 35.4\% (\(n=28\)) and 12.6\% (\(n=10\)) in the same order. In HT patients, the incidence of 25(OH)D3 deficiency was significantly higher than that of the control group \(p=0.025\) (Figure 2).

Euthyroidism, subclinical hypothyroidism, OHP and subclinical hyperthyroidism were diagnosed in 51 (56.6\%), 30 (33.3\%), 7 (7.77\%) and 2 (2.2\%) of the patients. None of the patients had overt hyperthyroidism. Because of the low numbers, patients with OHP and subclinical hyperthyroidism were omitted from statistical analysis. Patients with subclinical hypothyroidism and euthyroidism were similar in terms of age and sex distribution. 25(OH)D3 levels were not different among patients with euthyroidism and subclinical hypothyroidism. 25(OH)D3 levels of the euthyroid patients were significantly lower than those of the control group \(p=0.005\) (Table 2).

Table 3 shows all patients with HT grouped according to their 25(OH)D3 levels. Between groups, serum TSH was the parameter which showed significant differences \(p=0.029\). Serum TSH level was significantly higher in the patients with 25(OH)D3 deficiency as compared to patients with insufficiency \(p=0.011\). Thyroid hormone and autoantibody levels showed no differences between the groups.

In the total group of patients, serum 25(OH)D3 level was positively correlated with serum total T4 \((r=0.37; p=0.018)\) (Figure 3). There was no correlation between 25(OH)D3 levels and T3, TSH or thyroid autoantibodies.

### Discussion

The results of the present study demonstrated that patients with HT had significantly lower serum 25(OH)D3 levels compared with healthy controls and that the prevalence of 25(OH)D3 deficiency was higher in HT subjects. Recently, the effects of vitamin D on autoimmune diseases have
come to attention. While some clinical studies have shown a relationship between autoimmune thyroid diseases and serum vitamin D levels, others have not. In a study on 161 adult patients with HT, 25(OH)D3 levels were reported to be lower and prevalence of 25(OH)D3 insufficiency (<30 ng/mL) to be significantly higher in the patients than the 162 controls (22). In a study that involved 78 children (mean age: 12.0±2.8 years) with HT, 25(OH)D3 deficiency (5-14.9 ng/mL) and severe deficiency (<5 ng/mL) rates were higher than the control group (n=74) and an inverse correlation between vitamin D and anti-TPO levels were reported (20). Prevalence of 25(OH)D3 deficiency (<10 ng/mL) was also reported to be higher in adult patients with autoimmune thyroid disease (n=50) compared with patients with non-autoimmune thyroid disease and with healthy controls (23).

Moreover, in adult patients with HT, newly diagnosed and euthyroid both with no treatment (n=180) and in those previously diagnosed and on LT4 treatment (n=180), serum 25(OH)D3 levels were found to be lower than those in the control group (n=180), while 25(OH) D3 deficiency severity was correlated with duration of HT, thyroid volume and antibody levels (24). In a study that involved 6685 men, pre- and post-menopausal women, only in pre-menopausal women, mean serum 25(OH)D3 level was low in subjects with HT (25). In contrast, in a study with two case-control groups, serum 25(OH)D3 levels were not different in adult subjects with genetic susceptibility and in newly diagnosed thyroid autoimmunity compared to healthy controls (26). Additionally, in a study that involved 642 subjects between ages 16 and 60 years, mean serum 25(OH) D3 level was not different in anti-TPO positive and negative individuals (27).

These conflicting results can be partly related to the variations in study designs and in the definitions of vitamin D deficiency and in a lack of consensus regarding optimal serum 25(OH)D3 levels among healthy subjects. Thus, it is not easy to draw a conclusion about whether vitamin D deficiency is a risk factor for the development of autoimmune thyroiditis.

From a different point of view, it has been postulated that the low levels of serum 25(OH)D3 seen in autoimmune disease is a secondary phenomenon which reflects down regulation of vitamin D metabolism rather than being a causal factor leading to illness. Vitamin D receptor (VDR) dysfunction is proposed to be the key factor for the disease process (28). Once 1.25(OH)2D3 activates its receptor, expression of more than 900 genes is affected (29,30). One of the most important effects of VDR activation is its ability to increase the innate immune response which is important in the pathogenesis of autoimmune diseases (29,31,32). It has been postulated that low 25(OH)D3 is the result of VDR dysfunction and not the reason for autoimmunity. In this model, if VDR is disabled by disease, it becomes unable to express CYP24A1 which is the enzyme primarily responsible for inactivating 1.25(OH)2D3. Increased 1.25(OH)2D3 will in turn decrease 25(OH)D3 levels by reducing gene expression by the pregnane X nuclear

![Figure 3.](image)

There was a positive correlation between serum 25-hydroxyvitamin D3 levels and total thyroxine in the patients with autoimmune thyroiditis (r=0.37, p<0.05)

| Table 3: Comparison of thyroid function tests and thyroid autoantibodies of the patients at admission according to their 25-hydroxyvitamin D3 (25(OH)D3) status |
|---------------------------------------------------------------|
| Serum levels (mean ± SD) | 25(OH)D3 (ng/mL) | 20 (deficiency) (n=64) | 21 -29 (insufficiency) (n=16) | >30 (sufficiency) (n=10) | p-value |
| TSH 12.11±21.74** | 7.22±16.36** | 6.6±3.46 | 0.029* |
| fT3 3.58±0.93 | 3.89±1.07 | 3.69±0.68 | NS |
| fT4 1.20±1.26 | 1.95±3.86 | 1.13±1.17 | NS |
| Total T3 2.07±1.89 | 1.72±0.66 | 1.56±0.45 | NS |
| Total T4 5.86±2.63 | 8.43±3.43 | 8.03±1.36 | NS |
| Anti-TPO 537.59±372.3 | 395.0±337.94 | 317.10±292.01 | NS |
| Anti-Tg 379.67±746.99 | 411.16±619.78 | 131.10±129.01 | NS |

SD: standard deviation, TSH: thyroid stimulating hormone, fT3: free triiodothyronine, fT4: free thyroxine, anti-TPO: anti thyroid peroxidase, anti-Tg: anti-thyroglobulin
receptor and inhibiting expression of CYP27A1 which is an enzyme involved in conversion of vitamin D into 25(OH)D3 (33). In a clinical study focusing on VDR in 111 patients with HT, VDR gene TaqI TT and FokI FF genotypes were associated with increased risk for HT (34). Vitamin D levels of these patients were not measured, thus the association between VDR polymorphism and vitamin D status was not determined.

In the current study, although the prevalence rates of 25(OH)D3 insufficiency and sufficiency were not different in patients and controls, the prevalence of 25(OH)D3 deficiency was significantly higher in the HT patients. It was interesting to note that although statistically insignificant, the incidence of 25(OH)D3 insufficiency was higher in the control group. Vitamin D insufficiency was also encountered in our control group, but the patients with HT had vitamin D levels even lower. Based on the results of our study, we suggest that a serum 25(OH)D3 level of 20 ng/mL can be accepted as a critical cut-off level.

Thus in individuals with serum 25(OH)D3 <20 ng/mL, HT was observed 2.28 times more frequently as compared to ones with higher 25(OH)D3 levels. A recent study evaluating the effects of vitamin D in immune modulation showed a direct correlation of vitamin D levels with T regulatory cells and an inverse correlation with T effector cells, which are both related in the pathogenesis of autoimmune diseases. These authors suggested that there is an optimal vitamin D level to control immune regulation and pathogenic resistance (35). Clinical studies also suggested a U-shaped relation between vitamin D levels and different disorders so that both low and high levels were associated with the diseases (36,37,38,39,40,41). Although in the present study we were unable to evaluate high 25(OH)D3 levels because of the low numbers of patients and controls, our results do support the hypothesis that HT is associated with 25(OH)D3 levels below or equal to 20 ng/mL.

Besides affecting the thyroid gland through immune-mediated processes, vitamin D has also been shown to affect thyroid functions. In rat thyroid cells, vitamin D attenuates TSH-stimulated iodide uptake and cell growth (42). Vitamin D modulates TSH secretion of pituitary thyrotrophs by binding to specific binding sites (43). In a study on 2582 subjects between ages 15-44 years (44), in this study, mean serum TSH level was higher in patients with 25(OH)D3 deficiency compared to the patients with insufficiency and in all of the patients there was a positive correlation between serum total T4 and 25(OH)D3 levels. However, 25(OH)D3 levels were not different in patients with subclinical hypothyroidism and euthyroidism. Additionally, 25(OH)D3 levels were not different in patients with subclinical hypothyroidism and in the control group, whereas 25(OH)D3 levels were lower in euthyroid patients compared to the control group. Due to these contradictory results regarding the relationship between serum 25(OH)D3 levels and thyroid functions, it is difficult to make a clear association between them. Although there are studies showing correlation between serum 25(OH)D3 and anti-TPO levels (20,23) we were not able to find any correlation between these two parameters.

In conclusion, this study showed that possibly there is an association between vitamin D and HT, especially in individuals with 25(OH)D3 levels lower than 20 ng/mL. The mechanism for this association and whether it is a cause or effect relationship is not clear.

References

1. Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M; Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society; Vitamin D deficiency in children and its management: Review of current knowledge and recommendations. Pediatrics 2008;122:398-417.
2. Holick MF; Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006;116:2062-2072.
3. Holick MF; Vitamin D deficiency. N Engl J Med 2007;357:266-281.
4. DeLuca HF; Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80(Suppl 6):1689-1696.
5. Deluca HF; Cantorna MT; Vitamin D: Its role and uses in immunology. FASEB J 2001;15:2579-2585.
6. Mathieu C, Adorini L; The coming of age of vitamin D-dependent mechanism. Trends Mol Med 2002;8:174-179.
7. Schauber J, Dorschner RA, Coda AB, Büchau AS, Liu PT, Kiken D, Helfrich YR, Kang S, Elalieh HZ, Steinmeyer A, Zügel U, Bükke DD, Modlin RL, Gallo RL; Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest 2007;117:803-811. Epub 2007 Feb 8.
8. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, Tavera-Mendoza L, Lin R, Hanrahan JVW, Mader S, White JH; Cutting edge: 1.25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004;173:2909-2912.
9. Gombart AF, Borregaard N, Koefler HP; Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1.25-dihydroxyvitamin D3. FASEB J 2005;19:1067-1077.
10. Koizumi T, Nakao Y, Matsui T, Nakagava T, Matsuda S, Komoriya K, Kanai Y, Fujita T; Effects of corticosteroid and 1,24(R)-dihydroxyvitamin D3 administration on lymphoproliferation and autoimmune disease in MRL/Mp-lpr/lpr mice. Int Arch Allergy Appl Immunol 1985;77:396-404.
11. Mattner F, Smiroldo S, Galbiati F, Muller M, Di Lucia P, Poliani PL, Martino G, Panina-Bordignon P, Adorini L; Inhibition of TH1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1.25-dihydroxyvitamin D(3). Eur J Immunol 2000;30:498-508.
12. Lembre JM, Archer DC; 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991;87:1103-1107.
13. Cantorna MT, Hayes CE, DeLuca HF; 1,25-dihydroxyvitamin D3 reversibly blocks the progression of relapsing experimental encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996;93:7861-7864.
14. Larsson P, Mattsson L, Klareskog L, Johnsson C. A vitamin D analogue (mc 1288) has immunomodulatory properties and suppresses collagen-induced arthritis (cia) without causing hypercalcaemia. Clin Exp Immunol 1998;114:277-283.

15. Cantorna MT, Hayes CE, DeLuca HF. 1.25-dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1996;126:68-72.

16. Cantorna MT, Munsic K, Bemiss C, Mahon BD. 1.25-dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000;130:2648-2652.

17. Mathieu C, Waer M, Casteels K, Laureys J, Bouillon R. Prevention of type 1 diabetes in nmu mice by nonhypercalcemic doses of a new structural analog of 1.25-dihydroxyvitamin D3, kh1060. Endocrinology 1995;136:866-872.

18. Fournier C, Gepner P, Sadouk M, Charreire J. In vivo beneficial effects of cyclosporin A and 1.25-dihydroxy-vitamin D3 on the induction of experimental autoimmune thyroiditis. Clin Immunol Immunopathol 1990;54:53-63.

19. Chen W, Lin H, Wang M. Immune intervention effects on thyroid autoimmunity. J Huazhong Univ Sci Technol Med Sci 2002;22:343-345.

20. Camurdan OM, Döger E, Bideci A, Celik N, Cinaz P. Vitamin D status in children with Hashimoto thyroiditis. J Pediatr Endocrinol Metab 2012;25:467-470.

21. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-1930. Epub 2011 Jun 6

22. Tamer G, Arık S, Tamer I, Coksert D. Relative vitamin D insufficiency in Hashimoto’s thyroiditis. Thyroid 2011;21:891-896. Epub 2011 Jul 13

23. Kivity S, Agmon-Levin N, Zisappl M, Shapira Y, Nagy EV, Mader S, White JH. Large-scale in silico and microarray-based identification of direct 1.25-dihydroxyvitamin D3 target genes. Mol Endocrinol 2006;19:2685-2695. Epub 2005 Jul 7

24. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Kutzik SR, Ochoa MT, Schauer J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zügel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Medin RL. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006;311:1770-1773. Epub 2006 Feb 23

25. Wang TT, Tavera-Mendoza LE, Laperriere D, Libby E, MacLeod NB, Nagai Y, Bourdeau V, Konstorum A, Lallermant B, Zhang R, Mader S, White JH. Large-scale in silico and microarray-based identification of direct 1.25-dihydroxyvitamin D3 target genes. Mol Endocrinol 2006;19:2685-2695. Epub 2005 Jul 7

26. Effraimidis G, Badenhoop K, Tijssen JG, Wiersinga WM. Vitamin D deficiency and its relationship with thyroid autoimmunity. Thyroid 2014;24:655-661. Epub 2014 Jan 30

27. Choi YM, Kim WG, Kim TY, Bae SJ, Kim HK, Jeon MJ, Han JM, Lee SH, Baek JH, Shong YK, Kim WB. Low levels of serum vitamin D3 are associated with autoimmune thyroid disease in pre-menopausal women. Thyroid 2014;24:655-661. Epub 2014 Jan 30

28. Sister DC, Davis CD, Milner JA. The vitamin D and cancer epidemic: What dietetics practitioners need to know. J Am Diet Assoc 2011;111:524-527.

29. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Lanier K, Benjamin EJ, D’Agosto RB, Wolf M, Vasan RS. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117:503-511. Epub 2008 Jan 7

30. Ross AC, Manson JE, Abrams SA, Alioja JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA. The 2011 dietary reference intakes for calcium and vitamin D: What dietitians practitioners need to know. J Am Diet Assoc 2011;111:524-527.

31. Yaozhi D, Yavuz D, Tarcin O, Sancak S, Deyneli O, Akalin S. Vitamin D receptor gene Apa1, Taq1, Fok1 and BsmI polymorphisms in a group of turkish patients with Hashimoto’s thyroiditis. Minerva Endocrinol 2013;38:195-201.

32. Proal AD, Albert PJ, Marshall TG. Dysregulation of the vitamin D nuclear receptor may contribute to the higher prevalence of some autoimmune diseases in women. Ann N Y Acad Sci 2009;1173:252-259.

33. Yazici D, Yavuz D, Tarcin O, Sancak S, Deyneli O, Akalin S. Vitamin D receptor gene Apa1, Taq1, Fok1 and BsmI polymorphisms in a group of turkish patients with Hashimoto’s thyroiditis. Minerva Endocrinol 2013;38:195-201.

34. Song W, Wang TT, Tavera-Mendoza LE, Laperriere D, Libby E, MacLeod NB, Nagai Y, Bourdeau V, Konstorum A, Lallermant B, Zhang R, Mader S, White JH. Large-scale in silico and microarray-based identification of direct 1.25-dihydroxyvitamin D3 target genes. Mol Endocrinol 2006;19:2685-2695. Epub 2005 Jul 7

35. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Kutzik SR, Ochoa MT, Schauer J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zügel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Medin RL. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006;311:1770-1773. Epub 2006 Feb 23

36. Zeleniuch-Jacquotte A, Zheng W, Albanes D, Virtamo J, Wilkins LR, Yu K, Zeleniuch-Jacquotte A, Zheng W, Albanes D, Cai Q, Harvey C, Hayes R, Clipp S, Horst RL, Irish L, Koening K, Le Marchand L, Kolonel LN. Circulating 25-hydroxvitamin D and risk of pancreatic cancer: Cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol 2010;172:81-93. Epub 2010 Jun 18

37. Melamed ML, Michos ED, Post W, Arost B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008;168:1629-1637.

38. Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, Qi D, Patel AV, Helzlsouer KJ, Weinstein SJ, McCullough ML, Purdue MP, Ferron X, Snyder K, Virtamo J, Wilkins LR, Yu K, Zeleniuch-Jacquotte A, Zheng W, Albanes D, Cai Q, Harvey C, Hayes R, Clipp S, Horst RL, Irish L, Koening K, Le Marchand L, Kolonel LN. Circulating 25-hydroxvitamin D and risk of pancreatic cancer: Cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol 2010;172:81-93. Epub 2010 Jun 18

39. Tocher CD, Davis CD, Milner JA. The vitamin D and cancer conundrum: Aiming at a moving target. J Am Diet Assoc 2010;110:1492-1500.

40. Visser M, Deeg DJ, Puts MT, Seidell JC, Lips P. Low serum concentrations of 25-hydroxyvitamin D in older persons and the risk of nursing home admission. Am J Clin Nutr 2006;84:616-622.

41. Berg JP, Liane KM, Bjørkhove SB, Bjerø T, Torjesen PA, Haug E. Vitamin D receptor binding and biological effects of cholecalciferol analogues in rat thyroid cells. J Steroid Biochem Mol Biol 1994;50:145-150.

42. Sar M, Stumpf WE, DeLuca HF. Thyrotropes in the pituitary are target cells for 1.25-dihydroxy-vitamin D. Cell Tissue Res. 1980;209:161-166.

43. Proal AD, Albert PJ, Marshall TG. Dysregulation of the vitamin D nuclear receptor may contribute to the higher prevalence of some autoimmune diseases in women. Ann N Y Acad Sci 2009;1173:252-259.

44. Evliyaoğlu O et al. Vitamin D Deficiency and Hashimoto Thyroiditis. Endocrinology 2011;167:43-48. Epub 2011 Feb 23